Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Radiotherapy 5Mitomycin 5Fluorouracil 5Watchful Waiting 3Paclitaxel 3Nivolumab 3Cisplatin 3Vaccines 2Radiation 2Observation 2Light Coagulation 2Carboplatin 2Capecitabine 2pembrolizumab 1nanocis 1cemiplimab 1atezolizumab 1X-Rays 1Vaccines, Synthetic 1Technetium-99 1Taxes 1Specimen Handling 1Sigmoidoscopy 1Proctoscopy 1Phantoms, Imaging 1Papillomavirus Vaccines 1Octreotide 1Neoadjuvant Therapy 1Mitomycins 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anus Neoplasms × Proctoscopy × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡